Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Breast - NCCTG-N0338
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB) Cheville, Andrea L. , Sloan, Jeff A. , Northfelt, Donald W. ... - - Support Care Cancer - 2009 Manuscript - Primary - Primary - Symptom Inter - N01CB
Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52 Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Breast - N0337 , N98-32-52
NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM). Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - - Neuro-oncology - 2011 Abstract - Primary - Primary - Neuro-Onc - N0776
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin. Cancer Res. - 2013 Manuscript - Primary - Primary - Neuro-Onc - N0776
NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. Galanis, E. , Jaeckle, K. , Anderson, S. , Kaufmann, T. , Uhm, J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Neuro-Onc - N0776
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance). Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Breast - N0733
A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane. Hobday, T. , Rowland, K., Jr , Dueck, A. , Northfelt, D. , Lingle, W. ... - ASCO Breast - Breast Cancer Symposium - 2008 Abstract - Primary - Primary - Breast - NCCTG-N0537
Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging. Kaufmann, T. J. , Anderson, S. K. , Jaeckle, K. A. , Uhm, J. H. ... - SNO - 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors - 2011 Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N0776
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8 Kearns, Ann E. , Northfelt, Donald W. , Dueck, Amylou C. ... - - Support Care Cancer - 2010 Manuscript - Primary - Primary - Symptom Inter - N01C8
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831 Knutson, K. L. , Perez, E. A. , Ballman, K. , Erskine, C. L. , Fox, N. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary - Primary - Breast - N9831
Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain Knutson, Keith L. , Clynes, Raphael , Shreeder, Barath ... - - Cancer Res. - 2016 Manuscript - Secondary-not-in-original - Meta-Analysis - Breast - N0337 , N98-32-52 , N0938
Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer Knutson, Keith L. , Clynes, Raphael , Yeramian, Patrick ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Meta-Analysis - Breast - N0337 , N98-32-52 , N0938
Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735 Northfelt, D. W. , Dueck, A. C. , Flynn, T. P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - Breast - N0735
Phase II trial of polyglutamated paclitaxel (PPX) with capecitabine for metastatic breast cancer Northfelt, D. , Allred, J. , Liu, H. , Hobday, T. , Rodacker, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Breast - N0437
Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer Northfelt, DW , Allred, JB , Liu, H , Hobday, TJ , Rodacker, MW ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary - Primary - Breast - N0437
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Okuno, Scott H , Delaune, Robert , Sloan, Jeff A , Foster, Nathan R ... - - Cancer - 2008 Manuscript - Primary - Primary - Respiratory - N0021
Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437 Reinholz, M. , Kitzmann, K. , Hobday, T. , Northfelt, D. , Laplant, B. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - Breast - N0436 , N0437
Circulating tumor cells in North Central Cancer Treatment Group breast clinical trials Reinholz, M. , Kitzmann, K. , Tenner, K. , Hillman, D. , Hobday, T. ... - ISMRC - 7th International Symposium on Minimal Residual Cancer - 2009 Abstract - Secondary-not-in-original - Comprehensive - Breast - N0234 , N0336 , N0338 , N0436 , N0437
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437 Reinholz, Monica M. , Kitzmann, Kathleen A. , Tenner, Kathleen ... - - Clin. Cancer Res. - 2011 Manuscript - Secondary-not-in-original - Primary - Breast - N0336 , N0234 , N0338 , N0436 , N0437
N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer Roy, V. , Pockaj, B. , Northfelt, D. , Allred, J. , Liu, H. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Breast - N0338
A Phase II trial of docetaxel and carboplatin administered every two weeks as preoperative therapy for stage II or III breast cancer: NCCTG Study N0338 Roy, Vivek , Pockaj, Barbara A. , Allred, Jacob B. , Apsey, Heidi ... - - Am. J. Clin. Oncol. - 2013 Manuscript - Primary - Primary - Breast - N0338
N0321: A phase II study of bortezomib, paclitaxel, carboplatin, and radiotherapy for locally advanced non-small cell lung cancer Schild, S. E. , Molina, J. R. , Dy, G. K. , Rowland, K. M., Jr ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Respiratory - NCCTG-N0321
N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC) Schild, S. , Molina, J. , Dy, G. , Rowland, K., Jr , Sarkaria, J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Respiratory - NCCTG-N0321
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Schild, Steven E , McGinnis, William L , Graham, David ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2006 Manuscript - Primary - Primary - Respiratory - NCCTG-N0028
North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane Sideras, Kostandinos , Dueck, Amylou C. , Hobday, Timothy J. ... - - Clin. Breast Cancer - 2012 Manuscript - Primary - Primary - Breast - NCCTG-N0537
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Tan, W W , Hillman, D W , Salim, M , Northfelt, D W , Anderson, D M ... - - Ann. Oncol. - 2010 Manuscript - Primary - Primary - Breast - NCCTG-0332
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial Tan, W. W. , Dueck, A. C. , Flynn, P. , Steen, P. , Anderson, D. ... - - Ann. Oncol. - 2013 Manuscript - Primary - Primary - Breast - N0539
Phase I study of panobinostat (LBH589) and letrozole in post-menopausal metastatic breast cancer patients Tan, Winston W. , Allred, Jacob B. , Moreno-Aspitia, Alvaro ... - - Clin. Breast Cancer - 2016 Manuscript - Primary - Primary - Breast - NCCTG-N093B
A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321 Zhao, Yujie , Foster, Nathan R. , Meyers, Jeffrey P. ... - - J Thorac Oncol - 2015 Manuscript - Primary - Primary - Respiratory - NCCTG-N0321
